Development and significance of resistance to protease inhibitors in HIV-1-infected adults under triple-drug therapy in clinical practice

Journal of Medical Virology

Volumn 66, Issue 2, 2002, Pages 143-150

  Romano, Laura ^a   Venturi, Giulietta ^b   Giomi, Saverio ^c   Pippi, Luigi ^c   Valensin, Pier E ^a   Zazzi, Maurizio ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b Azienda Ospedaliera di Grosseto   (Italy)

^c UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

Antiretroviral therapy; CD4; Drug resistance; RNA

Indexed keywords

DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CLINICAL PRACTICE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; ITALY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; NONHUMAN; RNA ANALYSIS; TREATMENT FAILURE;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0036138037     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.2123     Document Type: Article

References (39)

1. High levels of drug-resistant human immunodeficiency virus variants in patients exhibiting increasing CD4 T cell counts despite virologic failure of protease inhibitor-containing antiretroviral combination therapy
2. Ritonavir and saquinavir combination therapy for the treatment of HIV infection
3. Development and significance of the HIV-1 reverse transcriptase M184V mutation during combination therapy with lamivudine, zidovudine, and protease inhibitors
4. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine
5. Resistance profiles in patients with viral rebound on potent antiretroviral therapy
6. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy
7. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection
8. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection
9. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy
10. Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy
11. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients
12. Dissociation of immunologic and virologic responses to highly active antiretroviral therapy
13. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor
14. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-Week follow-up
15. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
16. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: A survey of over 6000 samples
17. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society - USA Panel
18. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: Mutations, kinetics, and frequencies
19. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir
20. Salvage therapy with abacavir plus a nonnucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV cohort study
21. HIV protease inhibitors restore impaired T-cell proliferative response in vivo and in vitro: A viral- suppression-independent mechanism
22. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1
23. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor
24. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy
25. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
26. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort
27. Altered viral fitness of HIV-1 following failure of protease inhibitor-based therapy
28. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease
29. Correlation of response to treatment and HIV genotypic changes during phase III trials with saquinavir and reverse transcriptase inhibitor combination therapy
30. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC)
31. Human immunodeficiency virus reverse transcriptase and protease sequence database
32. Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo
33. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy
34. Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir
35. Ultrasensitive in-house reverse transcription-competitive PCR for quantitation of human immunodeficiency virus type 1 RNA in plasma
36. Outcome and predictors of failure of highly active antiretroviral therapy: One-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons
37. Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy failure
38. Long-read direct infrared sequencing of crude PCR products for prediction of resistance to HIV-1 reverse transcriptase and protease inhibitors
39. Clinical evaluation of an in-house reverse transcription-competitive PCR for quantitation of human immunodeficiency virus type 1 RNA in plasma